Source: The Next Web
CRYO-CELL, operating since 1989, is moving beyond cold storage to create the first standardized infrastructure for processing and validating cord blood stem cells at clinical scale—filling a 30-year gap where collection vastly outpaced usable inventory. Most banked cord blood remains therapeutically inaccessible; without standardized protocols for thawing, potency testing, and matching, collected samples become expensive waste rather than live treatments for leukemia, lymphoma, and emerging regenerative applications. This positions CRYO-CELL to capture both legacy inventory and new collections as FDA-regulated regenerative medicine moves from niche banking to protocol-driven deployment.